Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1,001 - 1,050 out of 12,304

Document Document Title
WO/2010/134027A1
Processes for preparing pimecrolimus starting from ascomycin, exploiting the selectivity characteristics of the purified enzymatic systems particularly regarding the selective functionalization of the hydroxyl groups present in position ...  
WO/2010/135564A2
Disclosed are compounds of formula (I)3 a derivative, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer. Also disclosed are methods of preparing compound of formula (I), a derivative, or a tau...  
WO/2010/130778A1
A method is described for the manufacture of pure 2-fluoro-ara-adenine of Formula (I) from 2-fluoro-ara-adenine triacetate using potassium carbonate (K2CO3), wherein the 2-fluoro-ara-adenine has a reduced dimer contents, as well as the c...  
WO/2010/131475A1
Disclosed is a stable crystal of 1-(2'-cyano-2'-deoxy-β-D-arabinofuranosyl)cytosine monohydrochloride. The crystal of 1-(2'-cyano-2'-deoxy-β-D-arabinofuranosyl)cytosine monohydrochloride shows characteristic peaks at 13.7°, 15.7°, 16...  
WO/2010/130233A1
The invention relates to 2-substituted-6-(substituted benzylamino)purine riboside derivatives of the general formula I. These compounds possess antiapoptotic, anti-inflammatory and differentiating activities. The invention relates also t...  
WO/2010/130726A1
Compounds of the formula (I) including any possible stereoisomers thereof, wherein: R4 is a monophosphate, diphosphate or triphosphate ester; or R4 is formula (II) or formula (III), R7 is optionally substituted phenyl, optionally substit...  
WO/2010/132513A1
A method of treating cancer using certain 2'-fluoro arabino nucleosides is provided. Also provided are compounds represented by the formula: ( I & A) wherein R is alkyl; and pharmaceutically acceptable salts thereof; and pharmaceutical c...  
WO/2010/127666A1
The invention relates to a method for producing phosphate-bridged nucleoside conjugates. In the method, a cyclosaligenyl nucleotide is produced first, to which a linker is added, which is used to perform the immobilization on a solid pha...  
WO/2010/127443A1
The present invention describes compounds of Formula I or a pharmaceutically acceptable salts or derivatives thereof. Compositions comprising compounds of Formula I are also described. The present invention further relates to a method of...  
WO/2010/128156A1
A 2,1,3-benzoxadiazole compound as a medicament according to the invention is one of the following compounds: 4-[(4-methoxybenzyl)thio]-7-nitro-2,1,3-benzoxadiazole, 2-[(7-nitro-2,1,3-benzoxadiazol-4- yl)thio]ethyl 4-methoxybenzene-1-sul...  
WO/2010/129666A1
Methods and compositions for immediately immunizing an individual against any molecule or compound are provided. The present invention is drected to an immunity linker with at least two sites; (1) at least one first binding site that bin...  
WO/2010/125200A1
This invention provides phosphate-modified nucleosides represented by the structural formula: wherein W is O or S, and wherein B, R1; R3 and R2. are s defined herein. These compounds are useful as substrates for DNA/RNA polymerases, and ...  
WO/2010/127210A1
Provided herein are compounds of Formula I, compositions comprising an effective amount of a compound of Formula I, and methods for reducing intraocular pressure comprising administering an effective amount of compounds of Formula I to a...  
WO/2010/126435A1
The present invention relates to novel compounds having an effect as i.a. galectin inhibitors, to the use of said compounds as a medicament as well as for the manufacture of a medicament for treatment of disorders relating to the binding...  
WO/2009/152095A3
Cyclic phosphate of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomers, salts (acid or basic addition salts), hydrates, solvates, or crystalline forms thereof, represented by t...  
WO/2010/106320A3
A process for the isolation and/or purification of a desired component, particularly 3'sialyl lactose, from whey, particularly cheese whey, comprising the steps of: optionally subjecting the whey to ultrafiltration to provide a protein c...  
WO/2010/002877A3
The present disclosure relates to the use and methods of manufacture of bicyclic nucleosides and nucleotides for the treatment and prevention of infectious and proliferative diseases, including microbial infections and cancer.  
WO/2010/121576A2
The invention provides compounds of formula I, wherein R1, R2 and R3 have values defined in the specification and a pharmaceutically acceptable salt thereof; or an optical isomer thereof; or a mixture of optical isomers, as well as compo...  
WO/2009/114814A3
Compounds containing nucleic acid bases or their precursors modified by enrichment at specific sites with heavy stable isotopes of elements naturally present at those sites in minute amount are useful for the treatment of diseases charac...  
WO/2010/121486A1
Prodrugs based on gemcitabine structure shown as formula (I) as well as their synthetic method and application are disclosed, wherein the definitions for the groups of a, b, c, d, E, Z and V are described in the specification. By modifyi...  
WO/2010/065787A3
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Tumor Suppressor genes, in particular, by targeting natural antisense polynucleotides of Tumor Suppressor genes. The invention...  
WO/2010/062404A3
This invention relates to synthesis of novel -N-FMOC protected nucleosides, succinates, phosphoramidites, corresponding solid supports that are suitable for oligo deoxy nucleosides and RNA oligonucleotide synthesis. Our discovery using N...  
WO/2010/118006A1
Provided herein are compounds used to inhibit the deamination enzyme responsible for the inactivation of therapeutic compounds, and methods of using them.  
WO/2010/113937A1
A process for producing an NC-type purine nucleoside readily has been demanded. Thus, disclosed is a process for producing a purine nucleoside represented by formula (I') or a salt thereof, which comprises reacting a pyrimidine nucleosid...  
WO/2010/090969A4
The present disclosure describes tetrahydropyran nucleoside analogs, oligomeric compounds prepared therefrom and methods of using the oligomeric compounds. More particularly, novel tetrahydropyran nucleoside analogs are provided having a...  
WO/2010/110775A1
This invention relates to the field of nucleic acid chemistry, more specifically to the field of compositions of matter that comprise triphosphates of modified 2'-deoxynucleosides and oligonucleotides that are formed when these are appen...  
WO/2010/065662A3
Oligonucleotide compounds modulate expression and/or function of Sirtuin 1 (SIRT1) polynucleotides and encoded products thereof. Methods for treating diseases associated with Sirtuin 1 (SIRT1) comprise administering one or more Oligonucl...  
WO/2010/065671A3
Oligonucleotide compounds modulate expression and/or function of Vascular Endothelial Growth Factor (VEGF) polynucleotides and encoded products thereof. Methods for treating diseases associated with Vascular Endothelial Growth Factor (VE...  
WO/2010/106320A2
A process for the isolation and/or purification of a desired component, particularly 3'sialyl lactose, from whey, particularly cheese whey, comprising the steps of: optionally subjecting the whey to ultrafiltration to provide a protein c...  
WO/2010/107487A2
New prodrugs are derived from highly water soluble parent drugs that exist as primary or secondary amines in their parent form. Lipophilic carrier groups are bonded to the parent drug via an amide linkage with additional linker elements ...  
WO/2009/116067A3
A compound of formula (I) or a tautomeric form, regioisomer, stereoisomer, solvate, N-oxide or pharmaceutically acceptable salts thereof; wherein 'a' - is selected from the group consisting of substituted or unsubstituted heterocycloalky...  
WO/2010/101526A1
Described is a new standalone diguanylate cyclase polypeptide having a GGDEF motif and a mutated I-site that does not bind c-di-GMP. We demonstrate that the production yield of c-di-GMP and analogues was significantly increased by mutati...  
WO/2010/101951A1
he present invention provides nucleosides of formula (1) and oligonucleotides comprising at least on nucleoside of formula (2): Another aspect of the invention relates to a method of inhibiting the expression of a gene in cell, the metho...  
WO/2010/101061A1
Disclosed are a compound having an antibacterial activity, more preferably an antibacterial nucleoside compound that can inhibit the activity of MraY to exert an antibacterial activity, particularly a novel derivative of Muraymycin that ...  
WO/2010/027512A4
The present invention relates to novel phosphoramidites, A-n-bz, C-n-bz, C-n-ac, G-n-ac and U are produced with an HPLC purity of greater than 98% and 31P NMR purity greater than 99%. A novel process of reverse 5'→ 3' directed synthesi...  
WO/2010/098365A1
Disclosed are a compound having an antibacterial activity and a derivative thereof, more preferably an antibacterial nucleoside compound that can inhibit the activity of MraY to exert an antibacterial activity and a derivative of the nuc...  
WO/2009/115893A3
The present patent application relates to the novel nucleoside derivatives and novel intermediates, which are useful to antiviral, anti tumor and immunomodulatory activity, method of treating diseases, conditions and/or disorders modulat...  
WO/2010/096201A2
The present invention relates to synthesis, purification and methods to obtain high purity novel 2'-arabino-O-methyl nucleosides and the corresponding phosphoramidites of various arabinonucleoside bases and introduction of such units int...  
WO/2004/028462A9
The present invention is a method for preparing 2-halo-6-aminopurines, and more specifically for preparing the clinical agent cladribine (2-chloro-2'-deoxyadenosine, C1dAdo, 4), a drug of choice against hairy-cell leukemia and other neop...  
WO/2010/093608A1
Provided are thieno[3,4-d]pyrimidin-7-yI and furo[3,4-d]pyrimidin-7-yl ribosides, riboside phosphates and prodrugs thereof as well as intermediates and methods of preparation. The compounds, compositions, and methods provided are useful ...  
WO/2010/003540A3
The present invention relates to an in-vitro method for the formation of megamitochondria in cells, wherein the cells are grown in a suitable fermentation medium acidulated with lactic acid to pH values between 5.3 and 6.7. The invention...  
WO/2010/090969A1
The present disclosure describes tetrahydropyran nucleoside analogs, oligomeric compounds prepared therefrom and methods of using the oligomeric compounds. More particularly, novel tetrahydropyran nucleoside analogs are provided having a...  
WO/2010/082128A1
The present invention relates to a novel and stereoselective synthetic process for the preparation of optically active cis-nucleoside derivatives of compound of Formula (I), wherein R3 represents H, F, Cl, C1-16 alkyl.  
WO/2010/079813A1
Provided is a method for efficiently manufacturing an inosine derivative represented by the general formula (8). (8) The method for manufacturing the inosine derivative (8) includes steps (a)-(d). Step (a): An inosine derivative (3) is m...  
WO/2010/081082A2
Phosphoramidate compounds derived from guanine bases having enhanced therapeutic potency are provided, and these compounds in particular have enhanced potency with respect to treatment of viral infections, such as hepatitis C virus. Phar...  
WO/2010/077578A1
The present disclosure describes bis-modified bicyclic nucleosides and oligomeric compounds that can be prepared comprising at least one of these bis-modified bicyclic nucleosides. More particularly, the bis-modified bicyclic nucleosides...  
WO/2010/075554A1
A process for preparing phosphoramidate prodrugs or cyclic phosphate prodrugs of nucleoside derivatives, which is a compound, its stereoisomers, salts (acid or basic addition salts), hydrates, solvates, or crystalline forms thereof.  
WO/2010/072146A1
The invention provides an isonucleoside compound which can significantly enhance the gene silencing efficiency of oligonucleotide modified by it and can keep the enzymatic stability of the oligonucleotide. The invention also provides a m...  
WO/2010/075517A2
A purified compound having activity against hepatitis C virus is disclosed.  
WO/2010/069047A1
The sialic acid-like sugar legionaminic acid is found as a virulence-associated surface glycoconjugate in Legionella pneumophila and Campylobacter coli. In this work, we have purified and biochemically characterized eleven candidate bios...  

Matches 1,001 - 1,050 out of 12,304